Table 2 Univariate and multivariate analyses for the overall survival (Cox hazard model)

Age ≥ 60 years

1.23

0.94–1.62

0.13

Estrogen receptor negative

1.53

1.14–2.07

0.005

1.79

1.29–2.48

<0.001

Recurrent disease

1.13

0.84-1.52

0.43

Central nervous system metastasis

0.99

0.51–1.94

0.98

Bone metastasis

1.40

1.06–1.85

0.018

1.51

1.10–2.07

0.011

Lung metastasis

1.04

0.78–1.37

0.81

Pleura/lymphangiopathy metastasis

1.25

0.90–1.73

0.19

Lymph node metastasis

1.07

0.80–1.43

0.66

Liver metastasis

1.85

1.40-2.44

< 0.001

1.61

1.14-2.28

0.007

Visceral metastasis

1.54

1.15-2.07

0.004

1.22

0.83-1.80

0.31

≥ 3 metastatic sites

1.43

1.08–1.88

0.013

1.26

0.91–1.75

0.16

Perioperative chemotherapy ^a

1.37

1.05-1.80

0.022

1.66

1.23-2.24

0.001

Disease-free interval<24 months

1.37

1.03–1.80

0.029

1.39

1.04–1.87

0.028

Therapy

Eribulin vs. non-Eribulin

1.11

0.84-1.47

0.47

0.85

0.63-1.15

0.29

Early-line eribulin ^b vs. non-Eribulin

1.28

0.92-1.78

0.15

Late-line eribulin ^c vs. non-Eribulin

0.96

0.69-1.33

0.79